Monica M. Mahathre, Padmashree C. G. Rida, Ritu Aneja. The more the messier: centrosome amplification as a novel
biomarker for personalized treatment of colorectal cancers[J]. The Journal of Biomedical Research, 2016, 30(6): 441-451. DOI: 10.7555/JBR.30.20150109
Citation:
Monica M. Mahathre, Padmashree C. G. Rida, Ritu Aneja. The more the messier: centrosome amplification as a novel
biomarker for personalized treatment of colorectal cancers[J]. The Journal of Biomedical Research, 2016, 30(6): 441-451. DOI: 10.7555/JBR.30.20150109
Monica M. Mahathre, Padmashree C. G. Rida, Ritu Aneja. The more the messier: centrosome amplification as a novel
biomarker for personalized treatment of colorectal cancers[J]. The Journal of Biomedical Research, 2016, 30(6): 441-451. DOI: 10.7555/JBR.30.20150109
Citation:
Monica M. Mahathre, Padmashree C. G. Rida, Ritu Aneja. The more the messier: centrosome amplification as a novel
biomarker for personalized treatment of colorectal cancers[J]. The Journal of Biomedical Research, 2016, 30(6): 441-451. DOI: 10.7555/JBR.30.20150109
Colon cancer is currently the third most common cancer and second most fatal cancer in the United States, resulting in approximately 600,000 deaths annually. Though colorectal cancer death rates are decreasing by about 3% every
year, disease outcomes could be substantially improved with more research into the drivers of colon carcinogenesis,
the determinants of aggressiveness in colorectal cancer and the identification of biomarkers that could enable choice
of more optimal treatments. Colon carcinogenesis is notably a slow process that can take decades. Known factors that
contribute to the development of colon cancer are mutational, epigenetic and environmental, and risk factors include
age, history of polyps and family history of colon cancer. Colorectal cancers exhibit heterogeneity in their features
and are often characterized by the presence of chromosomal instability, microscopic satellite instability, or CpG island
methylator phenotype. In this review, we propose that centrosome amplification may be a widespread occurrence in
colorectal cancers and could potently influence tumor biology. Moreover, the quantitation of this cancer-specific
anomaly could offer valuable prognostic information and pave the way for further customization of treatment based
on the organellar profile of patients. Patient stratification models that take into account centrosomal status could thus
potentially reduce adverse side effects and result in improved outcomes for colorectal cancer patients.
Bühler M, Fahrländer J, Sauter A, et al. GPER1 links estrogens to centrosome amplification and chromosomal instability in human colon cells. Life Sci Alliance, 2022, 6(1): e202201499.
DOI:10.26508/lsa.202201499. Print 2023 Jan
2.
Bühler M, Stolz A. Estrogens-Origin of Centrosome Defects in Human Cancer?. Cells, 2022, 11(3): 432.
DOI:10.3390/cells11030432
3.
Kalkan BM, Ozcan SC, Quintyne NJ, et al. Keep Calm and Carry on with Extra Centrosomes. Cancers (Basel), 2022, 14(2): 442.
DOI:10.3390/cancers14020442
4.
Jia ZH, Wang XG, Zhang H. Overcome cancer drug resistance by targeting epigenetic modifications of centrosome. Cancer Drug Resist, 2019, 2(2): 210-224.
DOI:10.20517/cdr.2018.010
5.
Li JA, Liu BC, Song Y, et al. Cyclin A2 regulates symmetrical mitotic spindle formation and centrosome amplification in human colon cancer cells. Am J Transl Res, 2018, 10(8): 2669-2676.
6.
Harrison LE, Bleiler M, Giardina C. A look into centrosome abnormalities in colon cancer cells, how they arise and how they might be targeted therapeutically. Biochem Pharmacol, 2018, 147: 1-8.
DOI:10.1016/j.bcp.2017.11.003